← All trials
NCT05357560
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Jul 31, 2025
- Completion date
- Jul 31, 2025
- First posted
- May 3, 2022
- Last posted
- Oct 24, 2022
- Enrollment
- 96
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OxfordLead sponsor
- Medical Research Council, The GambiaCollaborator
- Medical Research Council, The GambiaOverall official - principal investigator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.